Previous close | 437.94 |
Open | 436.55 |
Bid | 450.20 |
Ask | 452.20 |
Strike | 330.00 |
Expiry date | 2025-01-17 |
Day's range | 436.55 - 437.94 |
Contract range | N/A |
Volume | |
Open interest | 109 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.